rofecoxib

Rofecoxib (MK 966) binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with anti-inflammatory, antipyretic and analgesic properties and potential antineoplastic properties. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.

Parecoxib sodium is a prodrug of Valdecoxib and a selective, orally active COX-2 inhibitor that suppresses prostaglandin (PG) synthesis and alleviates pain and inflammation. Parecoxib sodium also acts as a cannabinoid 1 (CB1) receptor agonist (EC50=2.4 µM).